• Who we are
    • About us
    • Our values
    • Environmental, social & governance
    • Therapeutic areas
  • What we do
    • Consulting (Acsel Health)
    • HEOR & market access
    • Scientific communications
    • Patient engagement
  • Insights
  • News & Events
  • Join us
    • Careers
    • Reasons to join
  • Contact us
  • Menu Menu

Publication Library / Publications

Hospital resource use and cost associated with first-line anti-TNF therapy in patients with inflammatory bowel disease in the UK: comparison of subcutaneous (adalimumab) and intravenous (infliximab) therapies

Background

UK National Institute for Health and Care Excellence guidance states that if more than one biologic therapy option is available for patients with IBD the least expensive option should be used. However, limited economic data are available to inform these decisions.

Methods

Service evaluations (SE) were carried out in 2 UK hospitals between Feb and Sept 2016. The primary objective was to describe the overall cost of the first year of biologic therapy for patients with IBD treated with intravenous (infliximab [IFX]) or subcutaneous (adalimumab [ADA]) 1st-line anti-TNF therapy. SEs comprised a prospective time and motion evaluation of patient visits for anti-TNF treatment and a retrospective chart review of the resource utilisation associated with the first year of 1st-line anti-TNF-treatment in consenting patients with IBD treated with ADA or IFX for ≥12 months. Times for activities are reported as hh:mm:ss.

Results

For the time and motion study, 10 separate anti-TNF administration visits were observed for patients treated with ADA and IFX at each centre. The total time for all 10 administration visits in Centre 1 was 01:07:04 for ADA and 14:17:53 for IFX and in Centre 2 was 09:56:55 for ADA and 18:00:33 for IFX (see Table 1 for a breakdown of timings). The patient-reported time off work for anti-TNF administration visits was highest for patients treated with IFX at each centre (mean [SD] Centre 1: ADA 1.4 [1.5] hours/visit [n=9], IFX 3.3 [2.7] hours/visit [n=9]; Centre 2: ADA 3.7 [2.8] hours/visit [n=9], IFX 5.4 [3.1] hours/visit [n=8]). The total resource utilisation and related costs associated with the 1st year of anti-TNF therapy in Centre 1 (ADA n=16, IFX n=19) and Centre 2 (ADA n=19, IFX n=20) are summarised in Table 2. The drug cost/patient/year was similar for each anti-TNF at each centre (mean [SD] Centre 1: ADA £10,740.27 [445.43]/patient/year [n=16], IFX £11,319.08 [2,873.64]/patient/year [n=19]; Centre 2 ADA £11,398.22 [2,403.31]/patient/year [n=19], IFX £10,839.00 [ 2,626.54]/patient/year [n=20]).

Conclusions

The use of NHS resources associated with the use of ADA and IFX varies across the studied centres. The total cost/patient/year ranged between £363–£580 for ADA and £1563–£ 2067 for IFX. The total administration time of the anti-TNF ranged between 1 and 10h for ADA and 14 and 18h for IFX.

Authors J Hickey, S Keshav, S Gaugris, R Arasaradnam
Journal Journal of Crohn's and Colitis
Therapeutic Area Gastroenterology
Center of Excellence Real-world Evidence & Data Analytics
Year 2017
Read full article

Services

  • Consulting
  • HEOR & market access
  • Scientific communications
  • Creative communications
  • Patient engagement

Company

  • About Us
  • Our values
  • Environmental, social & governance
  • Our commitment to rare disease
  • Careers
  • Reasons to join
  • News & insights
  • Events
  • Locations & contact

Legal and Governance

  • Terms of use
  • Privacy notice
  • Cookie policy
  • IT security measures
  • Modern slavery statement
  • Disclosure UK – ABPI
  • Looking for OpenHealth Company?
  • Legal statements & documents
  • Global ethical business conduct code
  • Suppliers
footer-logo-mark
  • Twitter
  • Linkedin
  • Instagram
  • Facebook

© Copyright OPEN Health 2025. All rights reserved. OPEN Health is a registered trademark.

backtotop-arrow
Scroll to top